Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Statement on U.S. FDA Approval of Shelf Life Extension for Company's COVID-19 Vaccine

07/29/2021 | 10:04am EDT

NEW BRUNSWICK - We are pleased to confirm the U.S. Food & Drug Administration (FDA) has extended the shelf life for the Johnson & Johnson single-shot COVID-19 vaccine to six months.

The decision is based on data from ongoing stability assessment studies, which have demonstrated the vaccine is stable at six months when refrigerated at temperatures of 36 - 46 degrees Fahrenheit (2 - 8 degrees Celsius). Expiration dates will be updated on www.vaxcheck.jnj, where vaccine providers can confirm the latest expiration dates of our vaccine.

Evidence has demonstrated that Johnson & Johnson's single-shot COVID-19 vaccine offers protection against COVID-19 disease and prevents hospitalization and death, including in countries where viral variants are highly prevalent. A single-shot vaccine that provides this level of protection represents an important tool in the global fight against COVID-19, as we strive to help end this deadly pandemic.

We continue to work with the U.S. government and health authorities to support the use of our vaccine, including among those who wish to be fully vaccinated with one shot.

Cautions Concerning Forward-Looking Statements

This statement contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Contact:

Tel: (732) 524-0400

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about JOHNSON & JOHNSON
09/22JOHNSON & JOHNSON : Unit Signs Deal for HealthVerity Patient Data Platform
MT
09/22PRO BANKRUPTCY BRIEFING : J&J Beats Injury Lawyers on Talc Bankruptcy; Judge Questions Tal..
DJ
09/21JOHNSON & JOHNSON : Unit Collaborates With Persephone Biosciences On Stool Analysis
MT
09/21Shangula Rages Against West's Vaccine Nationalism
AQ
09/21Johnson & Johnson Data Shows COVID-19 Booster Shots 94% Effective Against Moderate to S..
MT
09/21Today on Wall Street: Markets at a pivot point
09/21JOHNSON & JOHNSON : Says New Data Show Booster Shot Increases COVID-19 Protection
MT
09/21J&J : Booster dose of its COVID shot prompts strong response
AQ
09/21JOHNSON & JOHNSON : Says New Data Shows a Booster of its One-Shot Vaccine Increases COVID-..
MT
09/21JOHNSON & JOHNSON : Announces Real-World Evidence and Phase 3 Data Confirming Strong and L..
PR
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 407 M - -
Net income 2021 22 809 M - -
Net Debt 2021 1 880 M - -
P/E ratio 2021 19,0x
Yield 2021 2,54%
Capitalization 432 B 432 B -
EV / Sales 2021 4,59x
EV / Sales 2022 4,38x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 163,93 $
Average target price 185,83 $
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY35.22%206 972
ABBVIE INC.-0.69%188 045